RegenMed Circles

𝐓𝐡𝐞 𝐏𝐨𝐰𝐞𝐫 𝐨𝐟 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐑𝐞𝐜𝐮𝐫𝐫𝐢𝐧𝐠 𝐒𝐚𝐚𝐒 𝐑𝐞𝐯𝐞𝐧𝐮𝐞𝐬 𝐈𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 At RegenMed, we believe that the best companies are those that can create and expand recurring revenues across a diverse client base. In a healthcare landscape that can be unpredictable, our approach sets us apart. With a vast market size in the U.S. alone, the healthcare industry offers countless opportunities. However, it's essential to recognize the challenges faced by pre-revenue companies trying to innovate. Did you know that only 14% of drugs and vaccines entering #clinicaltrials receive regulatory approval? It's a tough road for many! What makes RegenMed unique? We provide essential tools needed by medical providers and product manufacturers to conduct #clinicalstudies. Our patented product, Circles, is designed to meet those crucial needs. With a strong product-market fit and a commitment to monthly subscriptions, our revenue model allows for rapid scalability while keeping costs accessible for clients. Led by an experienced management team, we prioritize steady growth, cash earnings, and minimizing debt – because we know that in the world of healthcare, slow and steady wins the race. Join us on this journey as we transform the healthcare: https://hubs.li/Q02ZMlwz0 𝘛𝘩𝘪𝘴 𝘙𝘦𝘨 𝘊𝘍 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘪𝘴 𝘮𝘢𝘥𝘦 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘚𝘵𝘢𝘳𝘵𝘌𝘯𝘨𝘪𝘯𝘦 𝘗𝘳𝘪𝘮𝘢𝘳𝘺, 𝘓𝘓𝘊. 𝘛𝘩𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘪𝘴 𝘴𝘱𝘦𝘤𝘶𝘭𝘢𝘵𝘪𝘷𝘦, 𝘪𝘭𝘭𝘪𝘲𝘶𝘪𝘥, 𝘢𝘯𝘥 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘴 𝘢 𝘩𝘪𝘨𝘩 𝘥𝘦𝘨𝘳𝘦𝘦 𝘰𝘧 𝘳𝘪𝘴𝘬, 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘭𝘰𝘴𝘴 𝘰𝘧 𝘺𝘰𝘶𝘳 𝘦𝘯𝘵𝘪𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵.

Did you know that 𝐨𝐯𝐞𝐫 𝟒𝟗𝟏,𝟎𝟎𝟎 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 are currently underway worldwide? As the demand for innovative drugs, biologics, and medical devices rises, the importance of efficient data collection tools has never been greater. 📈 At 𝐑𝐞𝐠𝐞𝐧𝐌𝐞𝐝, we’re at the forefront of this transformation. Our unique platform, 𝐂𝐢𝐫𝐜𝐥𝐞𝐬, empowers individual physicians and industry leaders alike to conduct regulatorily compliant #clinicalstudies with ease. We’re not just equipping healthcare data miners with the tools they need; we’re ensuring they 𝐦𝐨𝐧𝐞𝐭𝐢𝐳𝐞 𝐭𝐡𝐞𝐢𝐫 𝐞𝐟𝐟𝐨𝐫𝐭𝐬 effectively. This is your opportunity to be part of a thriving ecosystem that's shaping the future of healthcare. Join us as we redefine #clinicaltrials and pave the way for innovation: https://lnkd.in/eZ8RVzPz

RegenMed’s business model is firmly rooted in the primacy of healthcare professionals. It is they who – by virtue of education, experience and disposition — are able to diagnose, treat, and engage with patients in a meaningful way. It is they who can identify the most important clinical issues, the most sensible and cost-effective approach to addressing those issues, and the areas where new products and treatment protocols will have the broadest impact. There are over 1 million active physicians in the U.S., and almost 2 million in the European Union. Very few of them do not want to exercise their best clinical judgment on behalf of their patients. Very few of them do not want the tools, data, and ethical financial incentive which will allow them to do so. Read more: https://lnkd.in/eQKjhvsj

#RegenMedClients #RWECircles

Every day, RegenMed helps physicians generate revenue and practice equity from the #realworldevidence inherent in their clinical cases. Contact us to find out more: https://lnkd.in/eMJy9J_t #RWECircles

“Zero to One” is a concept coined by Peter Thiel (PayPal, Palantir, Founders Fund). It denotes a company which not only identifies a new and large market, but also develops the ability to capture a good deal of that market’s value. RegenMed was founded – and operates – on the premise that #realworlddata is to healthcare what sand was to semiconductors or crude to refined petrochemicals. RWD is the commonplace – but uncaptured and unrefined raw materials – from which the most valuable #healthcareinnovations will emerge. Read more: https://lnkd.in/ezp7zvsx #RWECircles

As Michael and other evidence-based shockwave practitioners continue to collect clinically significant data, the resulting datasets become ever more valuable. Because each pathology - and treatment protocol-specific dataset is proprietary, it can be licensed to insurers, product, manufacturers, and healthcare AI learning models. Through Physicians Owned Circles, 85% of that license fee value accrues to the participating Circle Members themselves: https://lnkd.in/e9pVMXn2

AAHKS2024: We came, we saw, we conversed! RegenMed Circles’ first American Association of Hip and Knee Surgeons (AAHKS) conference had a little of everything: We caught up with our client and defacto conference “host” APEX Biologix and Todd Luoma. We enjoyed a masterclass symposia on kinematic alignment put on by new friends at Medacta USA, Inc.. I learned a few social media tips from guru Alex Archer, and even took a photo of the purply and popular Redefine Surgery team: https://lnkd.in/ebeJ9fgs Above all else, we confirmed why we were there: Data is king. Surgeons have it, manufacturers need it. There are many models of data obtainment. Most are expensive and burdensome, leading to narrow participation, cases, and results. Real-world data is changing that trend. Individual surgeons can quickly amass proprietary, licensable datasets from their everyday cases. Manufacturers can cost-effectively obtain high-quality clinical data from those enterprising customers. These data are increasingly playing roles in generating clinical evidence for regulators, payers and peers. RegenMed’s mission is to facilitate these direct, mutually-beneficial data exchanges between surgeons and their manufacturers. Only a live event like AAHKS can bring both sides to the table, iron out initial requirements and goals, and to validate this new yet proven approach. Now the real work begins. 

Please join us for a 𝐑𝐞𝐠𝐞𝐧𝐌𝐞𝐝, 𝐈𝐧𝐜. 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 𝐖𝐞𝐛𝐢𝐧𝐚𝐫, November 12, 2024 6:30 EST, GMT-5.   ➥ Disrupting the >$𝟏 𝐭𝐫𝐢𝐥𝐥𝐢𝐨𝐧 #valuebasedcare and #clinicalresearch 𝐦𝐚𝐫𝐤𝐞𝐭𝐬.   ➥ 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐟𝐢𝐭. Global medical provider and manufacturer client base. Strong monthly recurring revenue growth. ➥ 𝐅𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐔.𝐒. 𝐏𝐚𝐭𝐞𝐧𝐭: 𝘔𝘦𝘵𝘩𝘰𝘥 𝘢𝘯𝘥 𝘚𝘺𝘴𝘵𝘦𝘮 𝘍𝘰𝘳 𝘗𝘳𝘰𝘤𝘦𝘴𝘴𝘪𝘯𝘨 𝘓𝘢𝘳𝘨𝘦 𝘈𝘮𝘰𝘶𝘯𝘵𝘴 𝘖𝘧 𝘙𝘦𝘢𝘭-𝘞𝘰𝘳𝘭𝘥 𝘌𝘷𝘪𝘥𝘦𝘯𝘤𝘦.   For more information, see our Investors Page: https://lnkd.in/ebFneQyT *𝘛𝘩𝘪𝘴 𝘙𝘦𝘨 𝘊𝘍 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘪𝘴 𝘮𝘢𝘥𝘦 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘚𝘵𝘢𝘳𝘵𝘌𝘯𝘨𝘪𝘯𝘦 𝘗𝘳𝘪𝘮𝘢𝘳𝘺 𝘓𝘓𝘊, 𝘮𝘦𝘮𝘣𝘦𝘳 𝘍𝘐𝘕𝘙𝘈/𝘚𝘐𝘗𝘊. 𝘛𝘩𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘪𝘴 𝘴𝘱𝘦𝘤𝘶𝘭𝘢𝘵𝘪𝘷𝘦, 𝘪𝘭𝘭𝘪𝘲𝘶𝘪𝘥, 𝘢𝘯𝘥 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘴 𝘢 𝘩𝘪𝘨𝘩 𝘥𝘦𝘨𝘳𝘦𝘦 𝘰𝘧 𝘳𝘪𝘴𝘬, 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘭𝘰𝘴𝘴 𝘰𝘧 𝘺𝘰𝘶𝘳 𝘦𝘯𝘵𝘪𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵.

The increasing focus on real-world evidence plays a crucial role in improving #patientoutcomes in hip and knee surgeries. Join us at American Association of Hip and Knee Surgeons (AAHKS) Annual Conference to speak about how you can advance the field of #orthopedics through #realworlddata and #realworldevidence, and discover the opportunities they present. Let’s connect and collaborate to shape the future of healthcare together!